SUPN Shorts Pull Back Before Earnings as Acquisition Looms

Supernus Pharmaceuticals short sellers cut their exposure sharply in the week before today's earnings release, with positions falling 11.5% over the past seven days to 4.37 million shares, or 7.6% of the free float. That weekly decline is 1.7 standard deviations below the stock's typical week-on-week short interest change, making it an unusually large retreat rather than routine noise.

The pullback coincides with a stock that has barely moved. Shares closed at $41.08, down 0.3% on the week, trailing the median gain of 0.2% for its closest peers. Cost to borrow has also eased, falling 22% over the past week to 0.52%, having spiked as high as 0.75% earlier in October. Availability remains extremely loose at 2,281%, meaning roughly 23 shares are available to borrow for every one already on loan. There is no squeeze pressure here. Short sellers are covering into a calm lending market.

The broader context is the agreed takeover by Indivior. ORTEX forecasts an 84% probability that SUPN will be deleted from the Russell 2000 and Russell 3000, with an estimated trade date of 2 November and effective date of 3 November. The S&P SmallCap 600 deletion probability stands at 80%. In 351 past comparable Russell changes, the median stock moved minus 4.3% from announcement to effective date, and trade-day volume ran at 9.1 times normal. These are historical observations, not a forecast for this event. Analysts who have maintained coverage carry a mean price target of $60.50 against the current $41.08, though that gap largely reflects the pre-deal consensus rather than an independent view of near-term value.

The options market has grown less defensive than it was. The put/call ratio has dropped to 3.88 from above 4.40 a month ago, now sitting roughly one standard deviation below its 20-day average of 4.14. That is a high absolute ratio by most measures, but the direction of travel has been toward call activity rather than away from it, consistent with short sellers reducing exposure and some positioning for the deal close. The earnings report today will therefore test whether any operational update around ONAPGO, the company's Parkinson's therapy, changes the commercial story before the acquisition completes.